Aurobindo Pharma Launches Oral Contraceptives

Published: May 15, 2018

Aurobindo Pharma Limited has launched Mili™ and Tri-Mili™ lines of oral contraceptive tablets. Aurobindo’s Mili™ and Tri-Mili™ are an AB-rated generic equivalent to the reference listed drugs Ortho Cyclen® and Ortho Tri-Cyclen®. 

Mili™ is an estrogen/progestin COC, indicated for use by women to prevent pregnancy. Tri-Mili™ is an estrogen/progestin COC, indicated for use by women to prevent pregnancy and is also indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche.

 

Product Name

Strength

Brand Equivalent

Mili™ Norgestimate and Ethinyl Estradiol Tablets USP

0.250 mg / 0.035 mg

Ortho Cyclen®

Tri-Mili™ Norgestimate and Ethinyl Estradiol Tablets USP

0.180 mg / 0.035 mg, 0.215 mg / 0.035 mg 0.250 mg / 0.035 mg

Ortho Tri-Cyclen®

 

The combined products have an estimated market size of $389.7M for the twelve months ending February 2018 according to IQVIA*. 

About Aurobindo

Aurobindo is committed to a healthier life and our extensive product portfolio attests to this mission. Furthermore, we currently have some 23 approvals for oral contraceptive products. The first of this diverse product portfolio are  launching June 2018. We are excited for this launch and am attaching the press release and product images of the products.  

Greatly appreciate your professionalism and consideration in featuring this product launch release.


* IQVIA National Sales Perspectives: Retail and Non-Retail MAT February 2018

Back to news